Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy

Latreille, Elyse; Lee, Warren L.

doi:10.3390/v13020161

Cited by 27 publications

(17 citation statements)

References 198 publications

(229 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are no practical clinical guidelines to manage the viral coinfection in COVID-19 patients, and their treatment takes place based on previous experience learned from other outbreaks including influenza and SARS [4].…”

Section: Introductionmentioning

confidence: 99%

Viral Coinfection among COVID-19 Patient Groups: An Update Systematic Review and Meta-Analysis

Malekifar

Pakzad

Shahbahrami

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Coinfections have a potential role in increased morbidity and mortality rates during pandemics. Our investigation is aimed at evaluating the viral coinfection prevalence in COVID-19 patients. Methods. We systematically searched scientific databases, including Medline, Scopus, WOS, and Embase, from December 1, 2019, to December 30, 2020. Preprint servers such as medRxiv were also scanned to find other related preprint papers. All types of studies evaluating the viral coinfection prevalence in COVID-19 patients were considered. We applied the random effects model to pool all of the related studies. Results. Thirty-three studies including 10484 patients were identified. The viral coinfection estimated pooled prevalence was 12.58%; 95% CI: 7.31 to 18.96). Blood viruses (pooled prevalence: 12.48%; 95% CI: 8.57 to 16.93) had the most frequent viral coinfection, and respiratory viruses (pooled prevalence: 4.32%; 95% CI: 2.78 to 6.15) had less frequent viral coinfection. The herpesvirus pooled prevalence was 11.71% (95% CI: 3.02 to 24.80). Also, the maximum and minimum of viral coinfection pooled prevalence were in AMRO and EMRO with 15.63% (95% CI: 3.78 to 33.31) and 7.05% (95% CI: 3.84 to 11.07), respectively. Conclusion. The lowest rate of coinfection belonged to respiratory viruses. Blood-borne viruses had the highest coinfection rate. Our results provide important data about the prevalence of blood-borne viruses among COVID-19 patients which can be critical when it comes to their treatment procedure.

show abstract

Section: Introductionmentioning

confidence: 99%

Viral Coinfection among COVID-19 Patient Groups: An Update Systematic Review and Meta-Analysis

Malekifar

Pakzad

Shahbahrami

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Vasculotides is an Ang-1 mimetic provided with an anti-inflammatory effect. In animal models, it has been found to be helpful in various conditions such as hemorrhagic shock, pneumonia [222,223], strokes [224,225], and in preventing pathologic vascular leakage [226,227].…”

Section: Angiopoietin1 Mimeticsmentioning

confidence: 99%

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology

Milone

Bellofiore

Leotta

et al. 2022

JCM

View full text Add to dashboard Cite

Endothelial dysfunction (ED) is frequently encountered in transplant medicine. ED is an argument of high complexity, and its understanding requires a wide spectrum of knowledge based on many fields of basic sciences such as molecular biology, immunology, and pathology. After hematopoietic stem cell transplantation (HSCT), ED participates in the pathogenesis of various complications such as sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy (TA-TMA), idiopathic pneumonia syndrome (IPS), capillary leak syndrome (CLS), and engraftment syndrome (ES). In the first part of the present manuscript, we briefly review some biological aspects of factors involved in ED: adhesion molecules, cytokines, Toll-like receptors, complement, angiopoietin-1, angiopoietin-2, thrombomodulin, high-mobility group B-1 protein, nitric oxide, glycocalyx, coagulation cascade. In the second part, we review the abnormalities of these factors found in the ED complications associated with HSCT. In the third part, a review of agents used in the treatment of ED after HSCT is presented.

show abstract

“…Some countries take COVID-19 as an influenza, but extensive disease characterization data and research have shown that COVID-19 is not comparable to pandemic influenza, either in terms of its health hazards or its potential harm to society (Latreille and Lee, 2021). Evidence indicated that synthetic biology techniques play an important role in developing sensitive and specific diagnostic kits, vaccines and therapeutic drugs during the fighting against COVID-19.…”

Section: Synthetic Biology Involved In Pathogen Identification and Vaccine Developmentmentioning

confidence: 99%

Advances in Synthetic Biology and Biosafety Governance

Zhao

Zheng

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Tremendous advances in the field of synthetic biology have been witnessed in multiple areas including life sciences, industrial development, and environmental bio-remediation. However, due to the limitations of human understanding in the code of life, any possible intended or unintended uses of synthetic biology, and other unknown reasons, the development and application of this technology has raised concerns over biosafety, biosecurity, and even cyberbiosecurity that they may expose public health and the environment to unknown hazards. Over the past decades, some countries in Europe, America, and Asia have enacted laws and regulations to control the application of synthetic biology techniques in basic and applied research and this has resulted in some benefits. The outbreak of the COVID-19 caused by novel coronavirus SARS-CoV-2 and various speculations about the origin of this virus have attracted more attention on bio-risk concerns of synthetic biology because of its potential power and uncertainty in the synthesis and engineering of living organisms. Therefore, it is crucial to scrutinize the control measures put in place to ensure appropriate use, promote the development of synthetic biology, and strengthen the governance of pathogen-related research, although the true origin of coronavirus remains hotly debated and unresolved. This article reviews the recent progress made in the field of synthetic biology and combs laws and regulations in governing bio-risk issues. We emphasize the urgent need for legislative and regulatory constraints and oversight to address the biological risks of synthetic biology.

show abstract

Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy

Cited by 27 publications

References 198 publications

Viral Coinfection among COVID-19 Patient Groups: An Update Systematic Review and Meta-Analysis

Viral Coinfection among COVID-19 Patient Groups: An Update Systematic Review and Meta-Analysis

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology

Advances in Synthetic Biology and Biosafety Governance

Contact Info

Product

Resources

About